Prestige Consumer Healthcare (PBH) Long-Term Deferred Tax (2018)

Prestige Consumer Healthcare's (PBH) quarterly Long-Term Deferred Tax came in at $26000.0 in Q1 2018.

Prestige Consumer Healthcare (PBH) Long-Term Deferred Tax (2018) Analysis & Trends

Prestige Consumer Healthcare's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $26000.0 for Q1 2018.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $26000.0 in Q1 2018; TTM through Mar 2018 was $26000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $26000.0, changed N/A from the prior year.
Long-Term Deferred Tax held at $26000.0 in Q1 2018 per PBH's latest filing.
Across five years, Long-Term Deferred Tax topped out at $26000.0 in Q1 2018 and bottomed at $26000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Prestige Consumer Healthcare	2.34 Bn	2.28 Bn	157.37 Mn

Download Data

Date	Value
Mar 31, 2018	26,000.00